Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push
David Ricks, CEO, Eli LillyScott Mlyn | CNBCEli Lilly on Tuesday said it struck a $2.4 billion deal to acquire Dice Therapeutics in a bid to bulk up its treatment portfolio for immune-related diseases.Eli Lilly will pay $48 per share in…